Loading live market data…

Orchard Therapeutics plc

NASDAQ:ORTX

$16.7 USD

$0.05 (0.3%)

Volume
372.35K
Average Volume
92.98K
Market Capitalization
$380.11M
P/E Ratio
-27.38
Dividend Yield
0.00%
Price Target
$
Year High
$16.72
Year Low
$4.24
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.78
Source Headline
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA

Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom

globenewswire.com - 2026-04-30 02:30:00

Get ORTX Insider Trade Alerts

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

ORTX Price Target Summary

Last Month

$

0 analysts

Last Quarter

$

0 analysts

Last Year

$

0 analysts

All Time

$

0 analysts

ORTX Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2023-10-05 Stifel Downgrade Buy Hold
2023-10-04 Stifel Downgrade Buy Hold
2023-08-09 Oppenheimer Maintain Outperform Outperform
2023-08-08 Oppenheimer Maintain Outperform Outperform
2023-06-27 Cantor Fitzgerald Maintain Overweight Overweight
2023-06-26 Cantor Fitzgerald Maintain Overweight Overweight
2023-06-13 Oppenheimer Maintain Outperform Outperform
2023-06-12 Oppenheimer Maintain Outperform Outperform
2023-03-28 Cantor Fitzgerald Maintain Overweight Overweight
2023-03-27 Cantor Fitzgerald Maintain Overweight Overweight
2022-08-29 SMBC Nikko Downgrade Outperform Neutral
2022-05-13 Barclays Maintain Overweight Overweight
2022-04-01 SMBC Nikko Downgrade Outperform Neutral
2022-03-31 Cowen & Co. Downgrade Outperform Market Perform
2021-11-16 JP Morgan Downgrade Neutral Underweight
2021-11-05 Oppenheimer Maintain Outperform Outperform
2021-08-18 JP Morgan Downgrade Overweight Neutral
2021-01-07 Cantor Fitzgerald Maintain Overweight Overweight
2020-04-01 Oppenheimer Maintain Outperform Outperform
2019-09-17 Guggenheim Maintain Buy Buy
2019-09-05 Barclays Maintain Overweight Overweight
2019-08-30 Oppenheimer Maintain Outperform Outperform
2018-12-17 Goldman Sachs Upgrade Neutral Buy
2018-11-26 Wedbush Maintain Outperform Outperform
2018-11-26 Goldman Sachs Maintain Neutral Neutral
2018-11-26 JP Morgan Maintain Overweight Overweight
2018-11-26 Cowen & Co. Maintain Outperform Outperform